Galectins as Emerging Glyco-Checkpoints and Therapeutic Targets in Glioblastoma
Despite recent advances in diagnosis and treatment, glioblastoma (GBM) represents the most common and aggressive brain tumor in the adult population, urging identification of new rational therapeutic targets. Galectins, a family of glycan-binding proteins, are highly expressed in the tumor microenvi...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2021-12-01
|
| Series: | International Journal of Molecular Sciences |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1422-0067/23/1/316 |
| _version_ | 1797498814293082112 |
|---|---|
| author | Guillermo A. Videla-Richardson Olivia Morris-Hanon Nicolás I. Torres Myrian I. Esquivel Mariana B. Vera Luisina B. Ripari Diego O. Croci Gustavo E. Sevlever Gabriel A. Rabinovich |
| author_facet | Guillermo A. Videla-Richardson Olivia Morris-Hanon Nicolás I. Torres Myrian I. Esquivel Mariana B. Vera Luisina B. Ripari Diego O. Croci Gustavo E. Sevlever Gabriel A. Rabinovich |
| author_sort | Guillermo A. Videla-Richardson |
| collection | DOAJ |
| description | Despite recent advances in diagnosis and treatment, glioblastoma (GBM) represents the most common and aggressive brain tumor in the adult population, urging identification of new rational therapeutic targets. Galectins, a family of glycan-binding proteins, are highly expressed in the tumor microenvironment (TME) and delineate prognosis and clinical outcome in patients with GBM. These endogenous lectins play key roles in different hallmarks of cancer by modulating tumor cell proliferation, oncogenic signaling, migration, vascularization and immunity. Additionally, they have emerged as mediators of resistance to different anticancer treatments, including chemotherapy, radiotherapy, immunotherapy, and antiangiogenic therapy. Particularly in GBM, galectins control tumor cell transformation and proliferation, reprogram tumor cell migration and invasion, promote vascularization, modulate cell death pathways, and shape the tumor-immune landscape by targeting myeloid, natural killer (NK), and CD8<sup>+</sup> T cell compartments. Here, we discuss the role of galectins, particularly galectin-1, -3, -8, and -9, as emerging glyco-checkpoints that control different mechanisms associated with GBM progression, and discuss possible therapeutic opportunities based on inhibition of galectin-driven circuits, either alone or in combination with other treatment modalities. |
| first_indexed | 2024-03-10T03:38:45Z |
| format | Article |
| id | doaj.art-7d581e526e234e5cad92c1aa99f566e1 |
| institution | Directory Open Access Journal |
| issn | 1661-6596 1422-0067 |
| language | English |
| last_indexed | 2024-03-10T03:38:45Z |
| publishDate | 2021-12-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | International Journal of Molecular Sciences |
| spelling | doaj.art-7d581e526e234e5cad92c1aa99f566e12023-11-23T11:38:07ZengMDPI AGInternational Journal of Molecular Sciences1661-65961422-00672021-12-0123131610.3390/ijms23010316Galectins as Emerging Glyco-Checkpoints and Therapeutic Targets in GlioblastomaGuillermo A. Videla-Richardson0Olivia Morris-Hanon1Nicolás I. Torres2Myrian I. Esquivel3Mariana B. Vera4Luisina B. Ripari5Diego O. Croci6Gustavo E. Sevlever7Gabriel A. Rabinovich8Laboratorio de Investigación Aplicada en Neurociencias (LIAN), Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Fundación para la Lucha contra las Enfermedades Neurológicas de la Infancia (FLENI), Belén de Escobar B1625, ArgentinaLaboratorio de Investigación Aplicada en Neurociencias (LIAN), Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Fundación para la Lucha contra las Enfermedades Neurológicas de la Infancia (FLENI), Belén de Escobar B1625, ArgentinaLaboratorio de Glicomedicina, Instituto de Biología y Medicina Experimental (IBYME), Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Buenos Aires C1428, ArgentinaLaboratorio de Investigación Aplicada en Neurociencias (LIAN), Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Fundación para la Lucha contra las Enfermedades Neurológicas de la Infancia (FLENI), Belén de Escobar B1625, ArgentinaLaboratorio de Investigación Aplicada en Neurociencias (LIAN), Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Fundación para la Lucha contra las Enfermedades Neurológicas de la Infancia (FLENI), Belén de Escobar B1625, ArgentinaLaboratorio de Investigación Aplicada en Neurociencias (LIAN), Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Fundación para la Lucha contra las Enfermedades Neurológicas de la Infancia (FLENI), Belén de Escobar B1625, ArgentinaLaboratorio de Inmunopatología, Instituto de Histología y Embriología de Mendoza (IHEM), Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Mendoza C5500, ArgentinaLaboratorio de Investigación Aplicada en Neurociencias (LIAN), Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Fundación para la Lucha contra las Enfermedades Neurológicas de la Infancia (FLENI), Belén de Escobar B1625, ArgentinaLaboratorio de Glicomedicina, Instituto de Biología y Medicina Experimental (IBYME), Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Buenos Aires C1428, ArgentinaDespite recent advances in diagnosis and treatment, glioblastoma (GBM) represents the most common and aggressive brain tumor in the adult population, urging identification of new rational therapeutic targets. Galectins, a family of glycan-binding proteins, are highly expressed in the tumor microenvironment (TME) and delineate prognosis and clinical outcome in patients with GBM. These endogenous lectins play key roles in different hallmarks of cancer by modulating tumor cell proliferation, oncogenic signaling, migration, vascularization and immunity. Additionally, they have emerged as mediators of resistance to different anticancer treatments, including chemotherapy, radiotherapy, immunotherapy, and antiangiogenic therapy. Particularly in GBM, galectins control tumor cell transformation and proliferation, reprogram tumor cell migration and invasion, promote vascularization, modulate cell death pathways, and shape the tumor-immune landscape by targeting myeloid, natural killer (NK), and CD8<sup>+</sup> T cell compartments. Here, we discuss the role of galectins, particularly galectin-1, -3, -8, and -9, as emerging glyco-checkpoints that control different mechanisms associated with GBM progression, and discuss possible therapeutic opportunities based on inhibition of galectin-driven circuits, either alone or in combination with other treatment modalities.https://www.mdpi.com/1422-0067/23/1/316central nervous systemglioblastomagalectinsglycansangiogenesisimmunomodulation |
| spellingShingle | Guillermo A. Videla-Richardson Olivia Morris-Hanon Nicolás I. Torres Myrian I. Esquivel Mariana B. Vera Luisina B. Ripari Diego O. Croci Gustavo E. Sevlever Gabriel A. Rabinovich Galectins as Emerging Glyco-Checkpoints and Therapeutic Targets in Glioblastoma International Journal of Molecular Sciences central nervous system glioblastoma galectins glycans angiogenesis immunomodulation |
| title | Galectins as Emerging Glyco-Checkpoints and Therapeutic Targets in Glioblastoma |
| title_full | Galectins as Emerging Glyco-Checkpoints and Therapeutic Targets in Glioblastoma |
| title_fullStr | Galectins as Emerging Glyco-Checkpoints and Therapeutic Targets in Glioblastoma |
| title_full_unstemmed | Galectins as Emerging Glyco-Checkpoints and Therapeutic Targets in Glioblastoma |
| title_short | Galectins as Emerging Glyco-Checkpoints and Therapeutic Targets in Glioblastoma |
| title_sort | galectins as emerging glyco checkpoints and therapeutic targets in glioblastoma |
| topic | central nervous system glioblastoma galectins glycans angiogenesis immunomodulation |
| url | https://www.mdpi.com/1422-0067/23/1/316 |
| work_keys_str_mv | AT guillermoavidelarichardson galectinsasemergingglycocheckpointsandtherapeutictargetsinglioblastoma AT oliviamorrishanon galectinsasemergingglycocheckpointsandtherapeutictargetsinglioblastoma AT nicolasitorres galectinsasemergingglycocheckpointsandtherapeutictargetsinglioblastoma AT myrianiesquivel galectinsasemergingglycocheckpointsandtherapeutictargetsinglioblastoma AT marianabvera galectinsasemergingglycocheckpointsandtherapeutictargetsinglioblastoma AT luisinabripari galectinsasemergingglycocheckpointsandtherapeutictargetsinglioblastoma AT diegoocroci galectinsasemergingglycocheckpointsandtherapeutictargetsinglioblastoma AT gustavoesevlever galectinsasemergingglycocheckpointsandtherapeutictargetsinglioblastoma AT gabrielarabinovich galectinsasemergingglycocheckpointsandtherapeutictargetsinglioblastoma |